Stay updated on Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check4 days agoChange DetectedThe site’s interface revision was updated from v3.5.0 to v3.5.2 without changing the clinical study details shown on the page.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now includes updated definitions and timeframes for primary/secondary outcomes (PFS, OS, ORR), added PK data details, and an additional Naples, Italy site.SummaryDifference1.0%

- Check47 days agoChange DetectedThe page's revision indicator was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page shows a minor version update from Revision: v3.4.1 to Revision: v3.4.2; no study data or visible content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check90 days agoChange DetectedThe page now includes a glossary display option and a new QC metadata label 'Last Update Submitted that Met QC Criteria' along with a 'No FEAR Act Data' notice. The revision footer shows 'Revision: v3.4.0', replacing the previous 'v3.3.4'.SummaryDifference0.1%

Stay in the know with updates to Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.